PGEN
PRECIGEN, INC.
NASDAQ · Healthcare · Biotechnology · US
$7.78
−1.14%Next report
Analyst consensus
- Next report date
- Nov 12, 2026
- EPS estimate
- $0.09
- Revenue estimate
- $69.2M
Latest reported
- Last report date
- Aug 4, 2026
- EPS actual
- $0.05
- EPS estimate
- -$0.01
- Revenue actual
- $55.0M
- Revenue estimate
- $28.0M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +150.0%
- Revenue beats (12Q)
- 4
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 4, 2026 | -$0.01 | $0.05 | Beat 514.25% | $55.0M |
| May 13, 2026 | -$0.03 | -$0.02 | Beat 33.33% | $23.3M |
| Mar 25, 2026 | -$0.10 | -$0.01 | Beat 90.00% | $4.6M |
| Nov 13, 2025 | -$0.08 | -$0.11 | Miss -37.50% | $2.9M |
| Aug 12, 2025 | -$0.14 | -$0.11 | Beat 21.43% | $856.0K |
| Mar 19, 2025 | -$0.06 | -$0.04 | Beat 33.33% | $1.2M |
| Nov 14, 2024 | -$0.08 | -$0.09 | Miss -12.50% | $953.0K |
| Aug 14, 2024 | -$0.09 | -$0.10 | Miss -11.11% | $717.0K |
| Feb 13, 2024 | -$0.08 | -$0.13 | Miss -62.50% | $1.2M |
| Nov 9, 2023 | -$0.08 | -$0.08 | In line | $1.4M |
| Mar 6, 2023 | -$0.10 | -$0.11 | Miss -10.00% | $1.8M |
| Nov 9, 2022 | $0.10 | -$0.04 | Miss -140.00% | $16.7M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 12, 2026